LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
about
Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.MMSA-1 expression pattern in multiple myeloma and its clinical significance.Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma.
P2860
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
LDH is an adverse prognostic f ...... omib-based induction regimens.
@en
LDH is an adverse prognostic f ...... omib-based induction regimens.
@nl
type
label
LDH is an adverse prognostic f ...... omib-based induction regimens.
@en
LDH is an adverse prognostic f ...... omib-based induction regimens.
@nl
prefLabel
LDH is an adverse prognostic f ...... omib-based induction regimens.
@en
LDH is an adverse prognostic f ...... omib-based induction regimens.
@nl
P2093
P2860
P356
P1476
LDH is an adverse prognostic f ...... omib-based induction regimens.
@en
P2093
Albert Kwok Wai Lie
Joycelyn Sim
Sidney Tam
Yok Lam Kwong
P2860
P304
P356
10.1111/EJH.12434
P577
2014-10-18T00:00:00Z